pharmaceutical portfolio management

By Eric Bolesh, Director of Research In collaborations among pharmaceutical and biotech companies, conflicts inevitably arise — and they can spring from a host of different factors. Here are several of the most common issues that we hear about in...

By Ryan McGuire,Senior Research Analyst The megatrend of personalized medicine gained a significant boost of adrenaline recently as Vertex Pharmaceutical's cystic fibrosis drug, Kalydeco (ivacaftor), earned FDA approval. As with much of personalized medicine's...

By Shaylyn Pike,Senior Research Analyst Once upon a time, a brand team's quest ended at marketing approval; revenues would take care of themselves. Fast forward 20 years, and the industry faces a much more challenging road to brand success. Receiving...

By Jeremy Spivey,Senior Research Analyst After years of nurturing its global blockbuster and trying to prepare for patent expiration, Pfizer's Lipitor is finally open to direct generic competition in the United States. Ranbaxy, which has 180 days of...

By Michelle Vitko,Research Analyst Recently, I wrote a piece on the need for portfolio management teams to plan well ahead of patent expiry to maximize the number of tactics available to them to extend the lifecycle of the products in their portfolio....

By Michelle Vitko,Research Analyst The earlier pharmaceutical companies begin mapping out their portfolio management options, the more strategies will be available to them and the more success they will have in general. In fact, a senior director at a...

By Ryan McGuire,Senior Research Analyst This is the third installment in a blog series focusing on counter-generic strategies. You can read part 1 about the patent cliff and the second part on patent litigation. Under the FDA's Modernization Act Continue...

By Jeremy Spivey,Senior Research Analyst Preliminary survey results from our ongoing portfolio management study have already revealed some interesting details. Among them: * Government payer reimbursement rates for products are Continue reading “Portfolio...

This is the first entry in a series that will focus on countering generic competition and preserving pharmaceutical brand revenue. Much has been made about the slew of drugs that face the loss of patent protection in 2011. In all, experts estimate that $30...

Key Finding #4 from our Counter-Generics and Biosimilar Threats research: Short-term strategies are still the most popular, but line-extension tactics gaining favor. Over the past three years, short-term strategies, including litigation and defensive pricing,...